Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

A number of other equities research analysts also recently issued reports on TTPH. BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. BMO Capital Markets boosted their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a report on Wednesday, October 4th. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $8.00 to $15.00 in a report on Wednesday, July 26th. Finally, HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $12.96.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. Tetraphase Pharmaceuticals’s revenue for the quarter was up 28.2% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/28/tetraphase-pharmaceuticals-inc-ttph-upgraded-to-hold-at-zacks-investment-research.html.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider now directly owns 17,500 shares in the company, valued at $105,000. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. grew its stake in Tetraphase Pharmaceuticals by 6.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 7,866 shares during the period. Vanguard Group Inc. grew its stake in Tetraphase Pharmaceuticals by 16.4% during the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after buying an additional 230,420 shares during the period. Bank of New York Mellon Corp grew its stake in Tetraphase Pharmaceuticals by 3.4% during the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock worth $1,726,000 after buying an additional 6,114 shares during the period. Geode Capital Management LLC grew its stake in Tetraphase Pharmaceuticals by 17.0% during the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock worth $2,880,000 after buying an additional 45,554 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Tetraphase Pharmaceuticals by 180.4% during the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 408,078 shares during the period. Institutional investors own 40.92% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.